Queensland Centre for Medical Genomics in Australia Chooses LIMS for Next-Generation Sequencing Sample Tracking
News Nov 16, 2010
The next generation sequencing instruments at QCMG are generating terabytes of data on a weekly basis and sample tracking is quickly becoming unmanageable with existing Google docs, spreadsheets and other manual methods.
Dr Peter Wilson, executive officer at the Queensland Centre for Medical Genomics, stated, “We knew exactly what we needed when we decided to look for a commercial LIMS solution for our sequencing centre. We contacted GenoLogics because it has a proven LIMS system that can handle our needs today and will adapt to meet future requirements. Efficiently managing and tracking sample data in our lab is critical to the success of our research. We need to know where our samples are at every step of the workflow and our team needs to be able to access the history of the sample at any stage; the Geneus system provides these capabilities.”
Queensland’s high-profile sequencing centre turned to GenoLogics a few months ago, looking for a powerful LIMS solution that would enable researchers to manage and track their samples and metadata in a single centralized system. The GenoLogics solution, Geneus, provides unparalleled sample traceability and system flexibility. These capabilities were the primary considerations in the Queensland lab’s decision-making criteria. Queensland Centre for Medical Genomics will make use of the powerful and comprehensive sample genealogy view provided by Geneus that allows everyone in the lab to see (and interrogate) the history of a sample from sample submission to analysis and result reporting.
Change is constant in next-gen sequencing labs, so facilities such as the Queensland Centre for Medical Genomics need a flexible configurable LIMS that will enable users to make changes quickly without any programming delays; Geneus offers this capability.
The flagship project at The Queensland Centre for Medical Genomics (QCMG) is the sequencing of 500 pancreatic and ovarian cancer genomes as part of the International Cancer Genome Consortium (ICGC). Australia’s commitment to the ICGC has required the formation of a worldclass sequencing centre within the Institute for Molecular Bioscience (IMB), The University of Queensland (UQ). The Australian contingent of the ICGC initiative is based at the QCMG/IMB and will study the underlying changes that result in the development of pancreatic and ovarian cancer. The pancreatic cancer genome project includes significant contributions from research centers across the globe including the Ontario Institute for Cancer Research, Johns Hopkins University, the University of California, and the University of Verona.